Treatment outcomes in newly diagnosed malignant glioma in elderly patients

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2018-01, Vol.20 (suppl_1), p.i20-i20
• Main Authors: Dherijha, Muhammad, Alakandy, Likhith, Barrett, Chris
• Format: Article
• Language: English
• Subjects: Abstracts
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/nox238.088

Treatment Outcomes in newly diagnosed malignant glioma in elderly patients - A 4years retrospective analysis M.S.A Dherijha1, Ali Rajabian2, C.Barrett2L.Alakandy21Salford Royal Hospital, Manchester 2Institute of Neuroscience, Queen Elizabeth University Hospital Glasgow Introduction: The number of GBMs discussed in MDT is increasing as the prevalence of GBM is known to increase with age and overall population is ageing. There are few evidence based established protocols of optimum management of such cases. We aimed to assess the outcome of various modalities of treatments and their combinations. MethodRetrospective analysis of GBM discussed in neurooncology MDT of Institute of Neuroscience Glasgow between 2011–2014 with prospective follow-up. Data included the performance status at presentation and modalities of treatment combinations offered. Outcomes measured by survival time and functional status after aggressive therapies.Inclusion criteria was age above 70.Results: 126 patients were followed M:F ratio 54:46. Median age was 77 (70–90). 35% (n=44) were offered best supportive care due to poor performance, 3% (n=4) had only palliative radiotherapy, 61%(n=78) were offered combined surgery and oncological therapies. That ranged between biopsy alone, debulking and adjuvant chemoradiotherapy. Median Survival rate for best supportive care was 3.2 months, whist for palliative radiotherapy alone was 6.1 months and for combined surgical and oncological treatmentwas 11.6 months. A further 12%(n=16) were not offered oncological therapy after rediscusson in MDT following their surgical intervention with survival of 4.4 months.Conclusion Combined modality treatment clearly has survival benefits even for patients above 70. It can be targeted better by taking into consideration their presenting performance status and other comorbidities in MDT settings.